HAART and the heart: changes in coronary risk factors and implications for coronary risk in men starting antiretroviral therapy

Objectives.  To estimate changes in coronary risk factors and their implications for coronary heart disease (CHD) rates in men starting highly active antiretroviral therapy (HAART).

[1]  O. Kirk,et al.  The use of the Framingham equation to predict myocardial infarctions in HIV‐infected patients: comparison with observed events in the D:A:D Study , 2006, HIV medicine.

[2]  S. Yusuf,et al.  Obesity and the risk of myocardial infarction in 27 000 participants from 52 countries: a case-control study , 2005, The Lancet.

[3]  R. Weber,et al.  Lipid Profiles for Antiretroviral-Naive Patients Starting Pi- and Nnrti-Based Therapy in the Swiss HIV Cohort Study , 2005, Antiviral therapy.

[4]  Risto Lehtonen,et al.  Multilevel Statistical Models , 2005 .

[5]  B. Gazzard,et al.  Nevirapine and Efavirenz Elicit Different Changes in Lipid Profiles in Antiretroviral- Therapy-Naive Patients Infected with HIV-1 , 2004, PLoS medicine.

[6]  L. Iacoviello,et al.  HIV infection, HAART, and endothelial adhesion molecules: current perspectives. , 2004, The Lancet. Infectious diseases.

[7]  O. Kirk,et al.  Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? , 2004, The Journal of infectious diseases.

[8]  D. Costagliola,et al.  Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men , 2003, AIDS.

[9]  P. Reiss.  How bad is HAART for the HEART? , 2003, AIDS.

[10]  Rodolphe Thiébaut,et al.  Combination antiretroviral therapy and the risk of myocardial infarction , 2003 .

[11]  H. Masur,et al.  HIV infection and cardiovascular disease--is there really a link? , 2003, The New England journal of medicine.

[12]  Anne L. Taylor,et al.  Coronary heart disease in HIV-infected individuals. , 2003, Journal of acquired immune deficiency syndromes.

[13]  D. Arveiler,et al.  Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  A. Mocroft,et al.  Decline in the AIDS and death rates in the EuroSIDA study: an observational study , 2003, The Lancet.

[15]  S. Cole,et al.  Impact of HIV infection and HAART on serum lipids in men. , 2003, JAMA.

[16]  O. Kirk,et al.  Cardiovascular disease risk factors in HIV patients – association with antiretroviral therapy. Results from the DAD study , 2003, AIDS.

[17]  P Ducimetière,et al.  Are the Framingham and PROCAM coronary heart disease risk functions applicable to different European populations? The PRIME Study. , 2003, European heart journal.

[18]  T. Louis,et al.  Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. , 2003, The New England journal of medicine.

[19]  S. Sidney,et al.  Do Protease Inhibitors Increase the Risk for Coronary Heart Disease in Patients With HIV‐1 Infection? , 2002, Journal of acquired immune deficiency syndromes.

[20]  D. Cooper,et al.  Adverse effects of antiretroviral therapy , 2000, The Lancet.

[21]  K Henry,et al.  The Case for More Cautious, Patient-Focused Antiretroviral Therapy , 2000, Annals of Internal Medicine.

[22]  S M Marcovina,et al.  Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. , 1999, Circulation.

[23]  H. Schmidt,et al.  Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. , 1999, AIDS.

[24]  D L McGee,et al.  How generalizable are coronary risk prediction models? Comparison of Framingham and two national cohorts. , 1999, American heart journal.

[25]  P. Kissinger,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. , 1998, The New England journal of medicine.

[26]  David A. Cooper,et al.  A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors , 1998, AIDS.

[27]  G. Satten,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.

[28]  Manuel Battegay,et al.  Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study , 1997, BMJ.

[29]  P. Royston,et al.  Regression using fractional polynomials of continuous covariates: parsimonious parametric modelling. , 1994 .

[30]  P. Elwood,et al.  Plasma triglyceride and high density lipoprotein cholesterol as predictors of ischaemic heart disease in British men , 1992, British heart journal.

[31]  Gower Street,et al.  Health inequalities among British civil servants: the Whitehall II study , 1991, The Lancet.

[32]  A. Fehily,et al.  Caerphilly and Speedwell collaborative heart disease studies. The Caerphilly and Speedwell Collaborative Group. , 1984, Journal of epidemiology and community health.

[33]  S J Pocock,et al.  British Regional Heart Study: cardiovascular risk factors in middle-aged men in 24 towns. , 1981, British medical journal.

[34]  W. Kannel,et al.  An investigation of coronary heart disease in families. The Framingham offspring study. , 1979, American journal of epidemiology.

[35]  The Swiss Hiv Cohort Study,et al.  The Swiss HIV Cohort Study: Rationale, organization and selected baseline characteristics , 2005, Sozial- und Präventivmedizin.

[36]  P. Allhoff,et al.  The Framingham Offspring Study , 1991 .

[37]  K. Anderson,et al.  An updated coronary risk profile. A statement for health professionals. , 1991, Circulation.

[38]  Wolfgang Babisch,et al.  Traffic noise, work noise and cardiovascular risk factors : the Caerphilly and Speedwell collaborative heart disease studies , 1990 .